153 related articles for article (PubMed ID: 12844427)
1. Hormone replacement therapy and epithelial ovarian cancer: is there and association?
Riman T
J Br Menopause Soc; 2003 Jun; 9(2):61-8. PubMed ID: 12844427
[TBL] [Abstract][Full Text] [Related]
2. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
5. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study.
Hempling RE; Wong C; Piver MS; Natarajan N; Mettlin CJ
Obstet Gynecol; 1997 Jun; 89(6):1012-6. PubMed ID: 9170483
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma.
Sit AS; Modugno F; Weissfeld JL; Berga SL; Ness RB
Gynecol Oncol; 2002 Aug; 86(2):118-23. PubMed ID: 12144815
[TBL] [Abstract][Full Text] [Related]
8. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence.
Riman T; Persson I; Nilsson S
Clin Endocrinol (Oxf); 1998 Dec; 49(6):695-707. PubMed ID: 10209555
[TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis.
Garg PP; Kerlikowske K; Subak L; Grady D
Obstet Gynecol; 1998 Sep; 92(3):472-9. PubMed ID: 9721791
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy and ovarian cancer risk: a meta-analysis.
Zhou B; Sun Q; Cong R; Gu H; Tang N; Yang L; Wang B
Gynecol Oncol; 2008 Mar; 108(3):641-51. PubMed ID: 18221779
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
12. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
13. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies.
Negri E; Tzonou A; Beral V; Lagiou P; Trichopoulos D; Parazzini F; Franceschi S; Booth M; La Vecchia C
Int J Cancer; 1999 Mar; 80(6):848-51. PubMed ID: 10074916
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis.
Horn LC; Dietel M; Einenkel J
Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):4-12. PubMed ID: 15927347
[TBL] [Abstract][Full Text] [Related]
16. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies.
Riman T; Nilsson S; Persson IR
Acta Obstet Gynecol Scand; 2004 Sep; 83(9):783-95. PubMed ID: 15315588
[TBL] [Abstract][Full Text] [Related]
17. [Hormone replacement therapy and cancer].
Bjørge T; Tropé C
Tidsskr Nor Laegeforen; 1997 Jun; 117(15):2201-7. PubMed ID: 9235712
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Am J Epidemiol; 2002 Aug; 156(4):363-73. PubMed ID: 12181107
[TBL] [Abstract][Full Text] [Related]
19. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.
Mascarenhas C; Lambe M; Bellocco R; Bergfeldt K; Riman T; Persson I; Weiderpass E
Int J Cancer; 2006 Dec; 119(12):2907-15. PubMed ID: 16998830
[TBL] [Abstract][Full Text] [Related]
20. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
